Immutep Limited
IMMP
|
$2.25
2.27%
2.22%
90K
|
Health Technology
(0.0% 1d) (-9.8% 1m) (35.0% 1y) (0.0% 2d) (1.4% 3d) (-4.8% 7d) (Infinity% volume)
Earnings Calendar:
Market Cap: $ 267,487,776
http://www.immutep.com
Sec Filling | Patents | 2021 employees
(AU) Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. Its product is IMP321, which involves in clinical development for the treatment of breast cancer and melanoma. The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.
breast cancer cancer autoimmunity treatment
add to watch list Paper trade email alert is off
Press-releases
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761
Published: 2024-04-18 (Crawled : 12:00) - globenewswire.com
IMMP | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: 3.69%
H: 3.56%
C: -2.22%
imp761 institute research study
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
IMMP | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: -6.87%
H: 0.0%
C: 0.0%
tacti-004 lung positive cancer cell for trial
Immutep Announces First Clinical Data from 90mg Dosing of Efti
Published: 2024-03-05 (Crawled : 13:00) - globenewswire.com
IMMP | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: 6.38%
H: 7.6%
C: 4.4%
first
Immutep Quarterly Activities Report Q2 FY24
Published: 2024-01-30 (Crawled : 13:00) - globenewswire.com
IMMP | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: -0.47%
H: 7.98%
C: 0.47%
fy24 report
First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer
Published: 2024-01-04 (Crawled : 13:00) - globenewswire.com
IMMP | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: -0.43%
H: 5.22%
C: 4.78%
bavencio first cancer trial therapy
Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Published: 2023-12-21 (Crawled : 13:00) - globenewswire.com
IMMP | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: -0.43%
H: 0.0%
C: -1.72%
tacti-004 lung cancer cell trial
Immutep Receives A$2.6 million R&D Tax Incentive from French Government
Published: 2023-12-07 (Crawled : 13:00) - globenewswire.com
IMMP | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: 0.97%
H: 3.37%
C: -0.48%
Metastatic HR+/HER2− Breast Cancer Market is Expected to Showcase a Significant Growth at a CAGR of 9.3% by 2032, Predicts DelveInsight
Published: 2023-12-04 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.27%
H: 0.12%
C: 0.12%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.5%
H: 0.0%
C: 0.0%
IMMP | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: -0.49%
H: 3.41%
C: 0.0%
breast expected cancer growth market
Metastatic HER2-Positive Breast Cancer Market to Grow by 2032 at a 5.2% CAGR | DelveInsight
Published: 2023-11-29 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.35%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.09%
H: 0.0%
C: 0.0%
IMMP | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: 3.13%
H: 1.52%
C: 0.51%
breast cancer market
Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial
Published: 2023-11-22 (Crawled : 13:00) - globenewswire.com
IMMP | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: -0.27%
H: 2.15%
C: 1.08%
sight-003 expansion trial
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10